9.63
price up icon0.73%   0.07
pre-market  Pre-market:  9.72   0.09   +0.93%
loading
Regenxbio Inc stock is traded at $9.63, with a volume of 800.04K. It is up +0.73% in the last 24 hours and down -13.24% over the past month. Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$9.56
Open:
$9.56
24h Volume:
800.04K
Relative Volume:
1.33
Market Cap:
$474.71M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.5237
EPS:
-6.32
Net Cash Flow:
$-194.72M
1W Performance:
-9.75%
1M Performance:
-13.24%
6M Performance:
-39.32%
1Y Performance:
-51.92%
1-Day Range:
Value
$9.01
$9.80
1-Week Range:
Value
$8.865
$12.11
52-Week Range:
Value
$8.535
$28.80

Regenxbio Inc Stock (RGNX) Company Profile

Name
Name
Regenxbio Inc
Name
Phone
240-552-8181
Name
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Employee
344
Name
Twitter
@REGENXBIO
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
RGNX's Discussions on Twitter

Compare RGNX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
RGNX 9.63 474.71M 89.04M -241.08M -194.72M -6.32
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-01-23 Initiated Stifel Buy
Jun-02-23 Initiated Robert W. Baird Outperform
Jun-23-22 Initiated Berenberg Buy
Dec-15-21 Initiated Wedbush Neutral
Oct-19-21 Resumed Morgan Stanley Overweight
Jan-06-21 Upgrade Raymond James Outperform → Strong Buy
Dec-16-20 Initiated UBS Buy
Jun-25-20 Resumed BofA/Merrill Buy
May-13-20 Initiated RBC Capital Mkts Sector Perform
Aug-20-19 Upgrade SVB Leerink Underperform → Mkt Perform
Jun-18-19 Reiterated Chardan Capital Markets Buy
Jun-14-19 Resumed Raymond James Outperform
Jun-05-19 Reiterated Chardan Capital Markets Buy
Feb-25-19 Upgrade Evercore ISI In-line → Outperform
Feb-05-19 Upgrade Raymond James Outperform → Strong Buy
Dec-17-18 Reiterated Chardan Capital Markets Buy
Nov-08-18 Reiterated BofA/Merrill Neutral
Aug-08-18 Reiterated Chardan Capital Markets Buy
Jul-23-18 Downgrade BofA/Merrill Buy → Neutral
Jul-10-18 Reiterated Chardan Capital Markets Buy
May-09-18 Reiterated Barclays Overweight
Apr-09-18 Reiterated Chardan Capital Markets Buy
Mar-12-18 Downgrade Evercore ISI Outperform → In-line
Feb-13-18 Initiated Mizuho Neutral
Nov-09-17 Resumed Morgan Stanley Overweight
View All

Regenxbio Inc Stock (RGNX) Latest News

pulisher
Nov 20, 2024

Chardan Capital Reiterates Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology

Nov 19, 2024
pulisher
Nov 19, 2024

US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Nov 19, 2024
pulisher
Nov 19, 2024

Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World

Nov 19, 2024
pulisher
Nov 19, 2024

Raymond James maintains $18 target on RGNX after trial data - Investing.com

Nov 19, 2024
pulisher
Nov 18, 2024

Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline News & Insights

Nov 18, 2024
pulisher
Nov 18, 2024

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive

Nov 18, 2024
pulisher
Nov 18, 2024

REGENXBIO (NASDAQ:RGNX) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

What's Going On With REGENXBIO Shares Monday? - Benzinga

Nov 18, 2024
pulisher
Nov 18, 2024

Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch

Nov 18, 2024
pulisher
Nov 18, 2024

Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com

Nov 18, 2024
pulisher
Nov 18, 2024

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire

Nov 18, 2024
pulisher
Nov 17, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Nov 17, 2024
pulisher
Nov 17, 2024

REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Should You Buy? - Defense World

Nov 17, 2024
pulisher
Nov 17, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

Morgan Stanley bullish on Regenxbio stock, highlights gene therapy prospects By Investing.com - Investing.com South Africa

Nov 15, 2024
pulisher
Nov 15, 2024

Regenxbio down 13% ahead of data readout for muscular dystrophy asset - Seeking Alpha

Nov 15, 2024
pulisher
Nov 15, 2024

REGENXBIO (NASDAQ:RGNX) Shares Gap UpWhat's Next? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Redmile Group, LLC Increases Stake in Regenxbio Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

5 Analysts Have This To Say About Regenxbio - Benzinga

Nov 15, 2024
pulisher
Nov 15, 2024

REGENXBIO's (RGNX) Overweight Rating Reaffirmed at Morgan Stanley - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

REGENXBIO to Present First Functional Data for Novel Duchenne Gene Therapy RGX-202 | RGNX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India

Nov 14, 2024
pulisher
Nov 11, 2024

REGENXBIO FY2024 EPS Estimate Reduced by Leerink Partnrs - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

REGENXBIO (NASDAQ:RGNX) Price Target Raised to $40.00 at HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

HC Wainwright Has Positive View of REGENXBIO FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

HC Wainwright Increases Earnings Estimates for REGENXBIO - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 10, 2024
pulisher
Nov 09, 2024

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024
pulisher
Nov 08, 2024

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 08, 2024
pulisher
Nov 07, 2024

Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Regenxbio: Q3 Earnings Snapshot - The Washington Post

Nov 07, 2024
pulisher
Nov 06, 2024

RegenXBio Reports Progress Amid Revenue Decline - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Regenxbio Inc earnings missed by $0.05, revenue topped estimates - Investing.com Australia

Nov 06, 2024
pulisher
Nov 06, 2024

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Regenxbio Inc Holdin - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Sorrento Therapeutics (OTCMKTS:SRNEQ) & REGENXBIO (NASDAQ:RGNX) Financial Survey - Defense World

Nov 05, 2024
pulisher
Nov 04, 2024

REGENXBIO to Participate in Upcoming Investor Conferences - StockTitan

Nov 04, 2024
pulisher
Nov 03, 2024

When (RGNX) Moves Investors should Listen - Stock Traders Daily

Nov 03, 2024
pulisher
Oct 31, 2024

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track (NASDAQ:RGNX) - Seeking Alpha

Oct 31, 2024
pulisher
Oct 31, 2024

REGENXBIO (RGNX) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - cnhinews.com

Oct 30, 2024
pulisher
Oct 30, 2024

Assenagon Asset Management S.A. Lowers Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

RGNX stock touches 52-week low at $9.1 amid market challenges By Investing.com - Investing.com South Africa

Oct 29, 2024
pulisher
Oct 29, 2024

RGNX stock touches 52-week low at $9.1 amid market challenges - Investing.com

Oct 29, 2024

Regenxbio Inc Stock (RGNX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):